2
|
Morais-Rodrigues F, Silv Erio-Machado R, Kato RB, Rodrigues DLN, Valdez-Baez J, Fonseca V, San EJ, Gomes LGR, Dos Santos RG, Vinicius Canário Viana M, da Cruz Ferraz Dutra J, Teixeira Dornelles Parise M, Parise D, Campos FF, de Souza SJ, Ortega JM, Barh D, Ghosh P, Azevedo VAC, Dos Santos MA. Analysis of the microarray gene expression for breast cancer progression after the application modified logistic regression. Gene 2019; 726:144168. [PMID: 31759986 DOI: 10.1016/j.gene.2019.144168] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 09/21/2019] [Accepted: 10/11/2019] [Indexed: 01/02/2023]
Abstract
Methods based around statistics and linear algebra have been increasingly used in attempts to address emerging questions in microarray literature. Microarray technology is a long-used tool in the global analysis of gene expression, allowing for the simultaneous investigation of hundreds or thousands of genes in a sample. It is characterized by a low sample size and a large feature number created a non-square matrix, and by the incomplete rank, that can generate countless more solution in classifiers. To avoid the problem of the 'curse of dimensionality' many authors have performed feature selection or reduced the size of data matrix. In this work, we introduce a new logistic regression-based model to classify breast cancer tumor samples based on microarray expression data, including all features of gene expression and without reducing the microarray data matrix. If the user still deems it necessary to perform feature reduction, it can be done after the application of the methodology, still maintaining a good classification. This methodology allowed the correct classification of breast cancer sample data sets from Gene Expression Omnibus (GEO) data series GSE65194, GSE20711, and GSE25055, which contain the microarray data of said breast cancer samples. Classification had a minimum performance of 80% (sensitivity and specificity), and explored all possible data combinations, including breast cancer subtypes. This methodology highlighted genes not yet studied in breast cancer, some of which have been observed in Gene Regulatory Networks (GRNs). In this work we examine the patterns and features of a GRN composed of transcription factors (TFs) in MCF-7 breast cancer cell lines, providing valuable information regarding breast cancer. In particular, some genes whose αi ∗ associated parameter values revealed extreme positive and negative values, and, as such, can be identified as breast cancer prediction genes. We indicate that the PKN2, MKL1, MED23, CUL5 and GLI genes demonstrate a tumor suppressor profile, and that the MTR, ITGA2B, TELO2, MRPL9, MTTL1, WIPI1, KLHL20, PI4KB, FOLR1 and SHC1 genes demonstrate an oncogenic profile. We propose that these may serve as potential breast cancer prediction genes, and should be prioritized for further clinical studies on breast cancer. This new model allows for the assignment of values to the αi ∗ parameters associated with gene expression. It was noted that some αi ∗ parameters are associated with genes previously described as breast cancer biomarkers, as well as other genes not yet studied in relation to this disease.
Collapse
Affiliation(s)
- Francielly Morais-Rodrigues
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil.
| | - Rita Silv Erio-Machado
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Rodrigo Bentes Kato
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Diego Lucas Neres Rodrigues
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Juan Valdez-Baez
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Vagner Fonseca
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
| | - Emmanuel James San
- KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
| | - Lucas Gabriel Rodrigues Gomes
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Roselane Gonçalves Dos Santos
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Marcus Vinicius Canário Viana
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil; Federal University of Pará, UFPA, Brazil
| | - Joyce da Cruz Ferraz Dutra
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Mariana Teixeira Dornelles Parise
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Doglas Parise
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Frederico F Campos
- Department of Computer Science, Federal University of Minas Gerais, Brazil Av Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | | | - José Miguel Ortega
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Debmalya Barh
- Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur, West Bengal 721172, India
| | - Preetam Ghosh
- Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA
| | - Vasco A C Azevedo
- Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| | - Marcos A Dos Santos
- Department of Computer Science, Federal University of Minas Gerais, Brazil Av Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil
| |
Collapse
|
3
|
Sallabanda K, Dos Santos MA, Salcedo JBP, Diaz JAG, Calvo FA, Samblas J, Marsiglia H. Stereotactic radiosurgery as a salvage treatment option for atypical meningiomas previously submitted to surgical resection. J Radiosurg SBRT 2011; 1:133-139. [PMID: 29296307 PMCID: PMC5675470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/08/2011] [Accepted: 08/10/2011] [Indexed: 06/07/2023]
Abstract
BACKGROUND Surgery is the initial treatment for atypical meningiomas (AM), but in cases of recurrence, options become more limited. We present our results from salvage treatment with stereotactic radiosurgery (SRS) in previously surgically treated patients. METHODS Sixteen patients treated between 1993 and 2007 were retrospectively reviewed. The mean follow-up was of 66.5 months. Most of the patients (81.3%) presented a single tumor nodule, while 3 presented multicentric disease (18.7%). Lesion volumes varied from 0.8 to 12 cm3 (mean: 6.1 cm3). A dose of 12 to 16 Gy was prescribed according to isodose curves from 50 to 90%. RESULTS After SRS, 3 of the patients (18.8%) presented with tumor volume reduction, 7 (43.8%) remained stable, and 6 patients presented with tumor progression. The Kaplan-Maier-estimated progression-free survival (PFS) and overall survival (OS) were 70.3% and 87.1% at 5 years and 44% and 54.4% at 10 years. Age, sex, site and tumor volume were not significantly associated with the prognosis. Patients presenting with multicentric disease presented a poorer prognosis, although without statistical significance (p = 0.14). CONCLUSIONS SRS provided an effective and safe treatment for this group of patients with recurrent NBM. Patients who present with multicentric disease will probably fare more poorly.
Collapse
Affiliation(s)
- Kita Sallabanda
- Instituto Madrileño de Oncologia/Grupo IMO, Radiotherapy Department, Madrid, Spain
- Sanatório San Francisco de Asis, Neurosurgery Department, Madrid, Spain
| | - Marcos A Dos Santos
- Instituto Madrileño de Oncologia/Grupo IMO, Radiotherapy Department, Madrid, Spain
- Insitutut de Cancerologie Gustave Roussy, Radiotherapy Department, Ville Juif, France
| | - Jose B P Salcedo
- Instituto Madrileño de Oncologia/Grupo IMO, Radiotherapy Department, Madrid, Spain
- Sanatório San Francisco de Asis, Neurosurgery Department, Madrid, Spain
| | - Jose A G Diaz
- Instituto Madrileño de Oncologia/Grupo IMO, Radiotherapy Department, Madrid, Spain
- Sanatório San Francisco de Asis, Neurosurgery Department, Madrid, Spain
| | - Felipe A Calvo
- Instituto Madrileño de Oncologia/Grupo IMO, Radiotherapy Department, Madrid, Spain
- Hospital General Universitario Gregorio Marañon, Department of Oncology, Madrid, Spain
| | - Jose Samblas
- Instituto Madrileño de Oncologia/Grupo IMO, Radiotherapy Department, Madrid, Spain
- Sanatório San Francisco de Asis, Neurosurgery Department, Madrid, Spain
| | - Hugo Marsiglia
- Instituto Madrileño de Oncologia/Grupo IMO, Radiotherapy Department, Madrid, Spain
- Insitutut de Cancerologie Gustave Roussy, Radiotherapy Department, Ville Juif, France
| |
Collapse
|